1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.
The purpose of this study is to determinate progression free survival after 9 months of treatment.
Metastatic Colorectal Cancer
DRUG: Bevacizumab|DRUG: Capecitabine|DRUG: Oxaliplatine
Progression Free Survival, 9 months
Overall Response rate, 24 months|Overall survival, 24 months|Toxicity of the combination of capecitabine+oxaliplatin+bevacizumab, 24 months|Resection rate of hepatic or pulmonary metastases, 24 months
To look for a new chemotherapy management to get less acute and chronic toxicity and/or an easier administration treatment line.

This study tries to demonstrate an alternative chemotherapy scheme,continuous polychemotherapy regimen with less dose with the added effect of the monoclonal antibody Bevacizumab.